Coya Therapeutics shares are trading higher after the company announced it will report results from an investigator-initiated Phase 2 trial of low-dose interleukin-2 in patients with mild-to-moderate Alzheimer's disease.
Portfolio Pulse from Benzinga Newsdesk
Coya Therapeutics shares rose following the announcement of upcoming results from a Phase 2 trial of low-dose interleukin-2 for Alzheimer's disease.
October 28, 2024 | 7:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coya Therapeutics shares increased due to anticipation of Phase 2 trial results for a potential Alzheimer's treatment.
The announcement of upcoming trial results is a positive catalyst for Coya Therapeutics, as successful results could lead to further development and potential market approval, driving investor interest and stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100